- Home
- SDRL vs NAMS Comparison
SDRL vs NAMS Comparison
Compare SDRL & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDRL | NAMS |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SDRL | NAMS |
|---|---|---|
| Price | $45.41 | $22.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $56.00 | $46.75 |
| AVG Volume (30 Days) | 438.9K | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.61 | 32.81 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,437,000,000.00 | $22,503,000.00 |
| Revenue This Year | $5.22 | $17.96 |
| Revenue Next Year | $16.68 | $540.65 |
| P/E Ratio | $129.11 | ★ N/A |
| Revenue Growth | ★ 3.75 | N/A |
| 52 Week Low | $28.10 | $21.02 |
| 52 Week High | $55.47 | $42.21 |
Technical Indicators
Market Signals| Indicator | SDRL | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 37.90 |
| Support Level | $41.25 | $21.02 |
| Resistance Level | $45.50 | $37.26 |
| Average True Range (ATR) | 1.84 | 1.53 |
| MACD | -0.46 | 0.17 |
| Stochastic Oscillator | 4.38 | 26.31 |
Price Performance
Historical ComparisonAbout SDRL Seadrill Limited
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, and others. The company derives maximum revenue from Brazil.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.